Loading
A phase 2 trial of niraparib in lung cancer, run by ETOP IBCSG Partners Foundation, now recruiting.
Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC is a phase 2, interventional study registered as NCT05718323 by ETOP IBCSG Partners Foundation, with a registry enrolment figure of 44 participants, started 2023-12-20 and due to reach its primary completion in 2026-12. Interventions recorded: Niraparib. Conditions listed: SCLC,Extensive Stage; SLFN11-positive. Primary outcome: Progression-free survival (PFS) rate at 3 months by investigator assessment (according to RECIST v1.1). Lung eligibility wording from the registry: "* Histologically or cytologically confirmed ED-SCLC (stage IV according to the 8th TNM classification)". Sites: France, Germany, Italy, Spain, Switzerland. No results are recorded here; the registry entry is the source.
Shares PARP inhibitors, Extensive-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares ETOP IBCSG Partners Foundation, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Extensive-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Extensive-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Extensive-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Extensive-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Extensive-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Extensive-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.